Strictosamide

Strictosamide is a compound that can be isolated from Nauclea officinalis. Strictosamide has various activities such as anti-inflammatory, analgesic, anti-Plasmodium, antifungal, and promoting wound healing^{[1][2][3][4][5]}. In Vitro:Strictosamide (0-200 μM; 24 h) can inhibit the production of NO, TNF-α, and IL-1β, as well as the expression of iNOS in LPS (HY-D1056)-treated RAW 264.7 cells. The mechanism involves the inhibition of the NF-κB and MAPK pathways^[1].
Strictosamide (0.25-2 mg/mL) can inhibit the Mg²⁺-ATPase activity in isolated kidneys^[2]. In Vivo:Strictosamide (50-200 mg/kg; intraperitoneal injection; single dose) can increase the Na⁺, K⁺-ATPase activity in the mouse brain and inhibit the Mg²⁺-ATPase activity in the mouse kidneys^[2].
Strictosamide (10-40 mg/kg; intravenous injection; twice a day; 3 days) has anti-inflammatory and analgesic effects in multiple mouse models^[3].
Strictosamide (0.5-1.5 mg/kg; topical application; twice a day; 8 days) has a wound-healing-promoting effect in a rat wound model. The mechanism involves the activation of the PI3K/AKT signaling pathway^[4].